Natalie Holles Net Worth

Natalie Holles biography

Natalie C. Holles is Independent Director of the Company. Ms. Holles has served as Chief Executive Officer of Audentes Therapeutics, Inc. From May 2018 and until January 2020, Ms. Holles served as President and Chief Operating Officer of Audentes Therapeutics, Inc. and from August 2015 until May 2018, Ms. Holles served as Senior Vice President and Chief Operating Officer of Audentes Therapeutics, Inc. Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc. and previously held corporate development and commercial roles at InterMune, Inc. and Genentech, Inc. Ms. Holles holds an A.B. from Stanford University and an M.A. from the University of Colorado, Boulder.

What is the salary of Natalie Holles?

As the Independent Director of Rubius Therapeutics Inc, the total compensation of Natalie Holles at Rubius Therapeutics Inc is $641,926. There are 5 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.